FF-10101-01

DB16050InvestigationalSmall molecule

FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Formula / weight: C₂₉H₃₈N₈O₂ · 530.677 g/mol (avg)
Code names: FF-10101 · FF-10101-01

Resolves to

Compound

UNII7V7IHI0SYGCAS1472797-69-5

Structure

InChIKeyHJFSVYUFOXAVAA-YUAYGMJFSA-NSMILESCCCNC1=NC(NC2=CC=C(C=C2)C#N)=NC=C1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C

Targets

P36888FLT3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with FF-10101-01, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account